Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | NNMT | P40261 | 2/20 | 0.41 |
| ▸ | ACACB | O00763 | 6/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841924 | 0.80 | MAPT (0.62) | MAPTHPGDALDH1A1NNMTACACB | |
| SCHEMBL14480387 | 0.80 | ACACB (0.48) | MAPTALDH1A1NNMTACACBKMT2A | |
| SCHEMBL370097 | 0.79 | ALDH1A1 (0.49) | ESR1ESR2ALDH1A1ACACBACACA | |
| SCHEMBL30464201 | 0.79 | NNMT (0.67) | MAPTALDH1A1NNMTACACBSMN1; SMN2 | |
| SCHEMBL5013585 | 0.79 | NNMT (0.67) | MAPTALDH1A1NNMTACACBSMN1; SMN2 | |
| SCHEMBL27875916 | 0.79 | ALDH1A1 (0.46) | MAPTALDH1A1NNMTACACBKMT2A | |
| SCHEMBL3590924 | 0.78 | CA12 (0.51) | MAPTHTTLMNACA12CA1 | |
| SCHEMBL5943354 | 0.76 | KMT2A (0.63) | MAPTHTTLMNAESR1ESR2 | |
| SCHEMBL18101731 | 0.74 | MAPT (0.46) | MAPTALDH1A1NNMTACACBACACA | |
| SCHEMBL14480202 | 0.73 | ALDH1A1 (0.47) | MAPTALDH1A1NNMTACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470841-B2 | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof | SANOFI (FR) | 2013-06-25 | — | — | US | disclosed |
| US-20110183998-A1 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-28 | — | — | US | disclosed |
| EP-2310372-A2 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | Sanofi-Aventis (FR) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010003624-A2 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183998-A1 | HETEROCYCLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THE USE THEREOF | CS, CYP11B1, GPR119 | MAPT 4465/4885HTT 936/4885LMNA 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.